Ldl Cholesterol

Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.

An LDL target of less than 70 mg/dL with ezetimibe plus statin therapy was associated with lower risk for subsequent events after stroke/transient ischemic attack at 5 years vs. a target between 90 mg/dL and 110 mg/dL, researchers reported.

An expert consensus decision pathway recently issued by the American College of Cardiology addresses lipid-lowering therapies that were developed after the publication of the ACC/American Heart Association cholesterol guidelines in 2018.

In a phase 2 trial, obicetrapib, an investigational cholesteryl ester transfer protein inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks, researchers reported in Nature Medicine.

Data from an open-label extension of the FOURIER study show use of the PCSK9 inhibitor evolocumab for more than 7 years led to durable reductions in LDL and a reduction in CV events, including CV death, according to a speaker.

LOUISVILLE, Ky. — Changes in HDL level may be linked with SARS-CoV-2 infection risk and subsequent outcomes in COVID-19, a speaker reported.

Researchers have identified lipid cutoffs that may indicate elevated risk for MI and stroke among young adults aged 20 to 39 years without a history of diabetes, according to findings published in European Journal of Preventive Cardiology.

Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination therapy was noninferior to high-intensity statin monotherapy for major CV outcomes at 3 years, including CV death, data show.

The level of total cholesterol minus HDL and LDL was associated with progression of atherosclerosis, independently of traditional CV risk factors, according to data published in Circulation: Cardiovascular Imaging.